Could Spark Therapeutics’ merger with Roche finally get the ...

Spark Therapeutics’ merger with Roche has moved a step closer after the UK’s competition watchdog okayed the $4.8 billion deal, ahead of a regulatory deadline later today in the US.

Early data from Roche's NHL drug mosunetuzumab steals the sh...

There’s been a slew of scientific data coming from the American Society for Hematology (ASH) conference, but promising early data from Roche’s mosunetuzumab proved to be one of the major ta

FDA approves Roche's MRSA test, allowing for faster screenin...

The FDA has approved Roche’s MRSA test, a technology that could give healthcare providers the ability to detect infections faster than traditional culture-based tests.

Roche steps up Merck challenge with first-line NSCLC approva...

Mylan and Biocon launch Herceptin biosimilar in US

Mylan and Biocon have launched their Herceptin biosimilar Ogivri in the US, the second challenger to Roche’s breast and stomach cancer blockbuster.

Creating solutions, not products, in diabetes

Roche Diabetes Care’s Michael Goetzl explains how the company is spearheading a combined digital-pharmaceutical approach to diabetes and how pharma firms can best embrace holistic strategie